GRAIL
GRAL
$140.58
+6.01%
GRAIL, Inc. is a healthcare company focused on developing technologies for early cancer detection, centered on its multi-cancer early detection (MCED) blood test, Galleri, which is designed to detect all cancer types across all stages; the company operates in a single reportable segment providing MCED testing and services within the medical diagnostics and research industry. As a commercial-stage diagnostics platform with roughly 910 employees, GRAIL positions itself as a potential category-defining first mover in population-scale cancer screening rather than a conventional diagnostics lab, though it remains pre-profitability and dependent on payer and regulatory adoption. The current investor narrative is dominated by a binary FDA regulatory catalyst for Galleri alongside commercial traction, with recent headlines framing the stock as a high-risk, high-reward play following a failed NHS trial and a sharp share-price drawdown earlier in 2026. That narrative has flipped decisively bullish in recent weeks, with the stock more than doubling off its lows as the market prices in accelerating Galleri adoption and a favorable regulatory decision, while skeptics point to persistent cash burn and the absence of reimbursement scale.…
GRAL
GRAIL
$140.58
Related headlines
Investment Opinion: Should I buy GRAL Today?
The synthesized recommendation is Hold, reflecting a balanced view of GRAIL's high-risk, high-reward profile. The analyst consensus is 'buy' with a mean rating of 2.09, but the average target price of $112.40 implies -21.5% downside from the current price of $143.26, suggesting the stock has overshot near-term fundamentals. The core thesis is that Galleri's potential in MCED is transformative, but the valuation already embeds a high probability of FDA approval and commercial success, leaving limited margin of safety.
Supporting evidence includes revenue growth of 25.72% YoY in Q2 2026, a strong balance sheet with a current ratio of 11.97 and debt-to-equity of 0.038, and a cash position of $19.99 per share. However, profitability is deeply negative: gross margin is -28.12%, operating margin is -362.95%, and free cash flow is -$295.253 million trailing twelve months. The PS ratio of 21.37x is a steep premium to diagnostics peers, and the PEG ratio of 0.093 is distorted by negative earnings. The implied upside to the high analyst target of $175 is +22%, but the downside to the low target of $60 is -58%, creating an unfavorable risk/reward skew at current levels.
Key risks that could invalidate the thesis include FDA rejection or delay, slower-than-expected reimbursement adoption, and continued cash burn leading to dilution. The rating would upgrade to Buy if the stock pulls back to the $107-108 support zone or if FDA approval is granted with clear reimbursement pathways. It would downgrade to Sell if revenue growth decelerates below 20% YoY or if cash burn accelerates beyond $100 million per quarter. Relative to its own historical PS range of 14.5x to 79.95x, the current 21.37x is in the lower-middle portion, but relative to peers, the stock is overvalued. The verdict is that GRAL is fairly valued to overvalued at current levels, pricing in significant future success.
Sign up to view all
GRAL 12-Month Price Forecast
The forward-looking view is neutral with medium confidence, balancing the transformative potential of Galleri against a stretched valuation and binary regulatory catalyst. Revenue growth is respectable but not yet exponential, and the company remains deeply unprofitable with significant cash burn. Analyst sentiment is bullish on the business but has not caught up to the price, suggesting the stock may be ahead of fundamentals. The risk/reward is skewed to the downside at current levels, with a base case target of $100-130 and a bear case of $60-80. I would upgrade to bullish if the stock pulls back to the $107-108 support zone or if FDA approval is granted with clear reimbursement, and downgrade to bearish if revenue growth decelerates below 20% or cash burn accelerates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GRAIL's 12-month outlook, with a consensus price target around $116.10 and implied upside of -17.4% versus the current price.
Average Target
$116.10
0 analysts
Implied Upside
-17.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$60 - $175
Analyst target range
GRAIL is covered by 10 analysts with a consensus recommendation of "buy" (recommendation mean of 2.09 on a scale where lower is more bullish), and the average price target of $112.40 implies roughly -21.5% downside from the current price of $143.26 — meaning the stock has already blown through the consensus target after its recent vertical move. This is a critical signal: the consensus is bullish on the business but has not yet caught up to the price, so either analysts will revise targets sharply higher in coming weeks or the stock has overshot fundamentals. The consensus leans bullish on rating but the price-to-target relationship now leans cautious, and the estimated average EPS of -$9.08 (range -$10.18 to -$8.30) confirms analysts still model substantial losses. The target range is very wide — from a low of $60.00 to a high of $175.00 — a spread of nearly 3x that signals exceptionally high uncertainty and low conviction in any single outcome. The high target of $175 implies roughly +22% upside from current levels and likely assumes FDA approval, accelerating Galleri adoption, and multiple expansion on a much larger revenue base; the low target of $60 implies roughly -58% downside and prices in regulatory disappointment, slow reimbursement, and continued cash burn forcing dilution. Institutional ratings show a stable, mixed pattern with no recent downgrades: Canaccord Genuity reiterated Buy (Sept 28, 2026), Mizuho maintained Neutral (Sept 25), Baird reiterated Outperform (Sept 22), TD Cowen Buy (May 6), Piper Sandler Neutral (May 6), Guggenheim Buy (March 30), and Morgan Stanley Equal Weight (Feb 24) — a roughly even split between bullish and neutral, with no sell ratings. The absence of recent upgrades despite the massive price move suggests analysts are waiting for the FDA catalyst before re-rating, and the wide target dispersion combined with a 3.25 beta means investors should expect continued extreme volatility around binary events.
Bulls vs Bears: GRAL Investment Factors
The bull case rests on Galleri's potential to transform cancer screening, supported by 25.72% YoY revenue growth, a fortress balance sheet with a current ratio of 11.97, and massive relative strength (+77.24 points vs. SPY in one month). However, the bear case is equally compelling: a 21.37x PS ratio, deeply negative gross margins (-28.12%), and $295 million in annual cash burn suggest the stock is priced for perfection. The most important tension is the binary FDA catalyst—approval could justify the valuation and drive the stock toward the high target of $175, while rejection could send it plummeting toward the low target of $60. Currently, the bear evidence on valuation and profitability is stronger, but the bull momentum and analyst consensus (buy rating) provide a counterbalance. The stock's beta of 3.254 and max drawdown of -62.92% underscore the extreme risk involved.
Bullish
- Revenue growth accelerating: Q2 2026 revenue grew 25.72% YoY to $44.687 million, up from $35.544 million in Q2 2025, and the sequential trend from Q1 2026 ($40.785 million) shows continued commercial traction. This growth is driven by Galleri adoption, and with FDA approval and reimbursement, the addressable market could expand dramatically.
- Fortress balance sheet: Debt-to-equity is just 0.038 and the current ratio is 11.97, providing substantial liquidity. Cash per share was $19.99 as of Q2 2026, giving GRAIL a multi-year runway to fund operations without immediate solvency risk.
- Massive relative strength: GRAL has outperformed SPY by 77.24 percentage points over the past month and 143.17 points over six months, with the stock up 121.32% over one year. This idiosyncratic momentum reflects a catalyst-driven re-rating, not broad market beta.
- Analyst consensus bullish: 10 analysts rate GRAL a 'buy' with a mean recommendation of 2.09, and the average price target of $112.40 implies -21.5% downside only because the stock has already surged past it. The high target of $175 suggests significant upside if FDA approval materializes.
Bearish
- Extreme overvaluation on sales: The trailing PS ratio of 21.37x and EV/Sales of 31.17x are steep premiums to typical diagnostics peers, which trade in the mid-single-digit to low-double-digit sales multiples. This valuation prices in near-flawless execution and leaves little room for error.
- Deeply negative margins: Q2 2026 gross margin was -28.12%, with gross profit of -$12.566 million, meaning cost of revenue exceeded revenue. The trailing operating margin is -362.95%, and net margin is -246.7%, highlighting a business that is far from profitability.
- Significant cash burn: Trailing twelve-month free cash flow is -$295.253 million, and Q2 2026 free cash flow was -$81.162 million. The company relied on $113.611 million of common stock issuance in Q2 2026, and continued dilution is a real risk if burn persists.
- Analyst targets below price: The average analyst target of $112.40 implies -21.5% downside from the current price of $143.26, and the low target of $60 implies -58% downside. The consensus has not caught up to the recent price surge, signaling potential overextension.
GRAL Technical Analysis
GRAIL is in a violent, parabolic uptrend that has overwhelmed its prior downtrend: the stock is up 121.32% over the past year and 160.52% over six months, and at $143.26 it sits at roughly 93% of its 52-week range (52-week low $41.50, high $151.457), meaning it is trading just below its highs rather than in the middle of a range. This positioning signals powerful momentum but also meaningful overextension risk, particularly given a max drawdown of -62.92% within the past year that shows how quickly this name can reverse. The move from the April 2026 area near $45-50 to above $140 represents a near-tripling, so the trend is unmistakably bullish but increasingly vulnerable to profit-taking. Recent momentum is accelerating rather than decelerating: the 1-month change is +77.83% versus +107.29% over three months, and the last two weeks alone saw the stock gap from $80.77 on September 18 to $107.97 on September 21 and then to $143.26 by October 2, a roughly 77% move in under three weeks. Relative strength confirms the divergence from the market — GRAL's 1-month relative strength versus SPY is +77.24 points (SPY +0.59% vs. GRAL +77.83%) and its 6-month relative strength is +143.17 points — indicating this is an idiosyncratic, catalyst-driven re-rating rather than a beta-driven move. The 12.29 short ratio implies heavily shorted positioning that may be fueling a squeeze, which can amplify upside but also makes the tape fragile once covering exhausts. Key levels are well defined: immediate resistance is the 52-week high at $151.457, and a decisive breakout above that level would likely require a fundamental catalyst (FDA approval or reimbursement news) to be sustained, while the first meaningful support sits at the September breakout zone around $107-108, with deeper support at the 52-week low of $41.50. The stock's beta of 3.254 means it is more than three times as volatile as the S&P 500, so a 10% market drawdown could translate into a 30%+ move in GRAL — position sizing must account for this extreme sensitivity, and the -62.92% max drawdown is a live reminder that stop discipline is essential. A breakdown below $107 would signal the squeeze has exhausted and the stock is retracing toward its pre-catalyst base, while a break above $151.46 would open blue-sky territory with no overhead resistance.
Beta
2.84
2.84x market volatility
Max Drawdown
-62.9%
Largest decline past year
52-Week Range
$42-$166
Price range past year
Annual Return
+97.6%
Cumulative gain past year
| Period | GRAL Return | S&P 500 |
|---|---|---|
| 1m | +81.4% | +2.1% |
| 3m | +95.3% | +3.1% |
| 6m | +208.1% | +14.6% |
| 1y | +97.6% | +16.0% |
| ytd | +58.2% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GRAL Fundamental Analysis
Revenue is growing but from a small base and with lumpy sequential progression: Q2 2026 revenue was $44.687 million, up 25.72% year-over-year from $35.544 million in Q2 2025, continuing a multi-quarter climb from $40.785 million in Q1 2026, $43.597 million in Q4 2025, $36.194 million in Q3 2025, and $31.837 million in Q1 2025. The YoY growth rate of roughly 26% is respectable for a diagnostics launch but is decelerating relative to the scale of the valuation being assigned, and the sequential pattern is choppy (Q4 2025 revenue of $43.597 million actually exceeded Q1 2026's $40.785 million), suggesting commercial traction is not yet on a smooth exponential curve. With no revenue segment breakdown provided, the entire top line rests on Galleri testing volume and pricing, meaning the investment case is effectively a single-product bet on MCED adoption. For the growth trend to justify the current market capitalization, revenue would need to inflect sharply as reimbursement and FDA clearance broaden the addressable market. Profitability remains deeply negative and margins are erratic: Q2 2026 net income was -$110.247 million on $44.687 million of revenue, a net margin of roughly -246.7%, and gross profit was actually negative at -$12.566 million (gross margin of -28.12%), meaning the cost of revenue exceeded revenue in the quarter. The trailing gross margin of -42.52% and operating margin of -362.95% underscore that GRAIL is spending far more to deliver and develop its tests than it collects, with Q2 2026 operating expenses of $161.217 million (including $47.429 million R&D and $37.657 million selling and marketing) dwarfing revenue. There is some quarter-to-quarter noise — Q1 2026 gross margin was positive at 47.91% versus -28.12% in Q2 2026 — but the trend is clearly one of a company investing heavily ahead of scale, and the path to profitability depends on gross margin normalization plus operating leverage that has not yet materialized. The balance sheet is the strongest part of the story: debt-to-equity is just 0.038, the current ratio is an exceptionally high 11.97, and cash per share was $19.99 as of Q2 2026, giving GRAIL substantial liquidity runway. However, cash burn is significant — trailing twelve-month free cash flow is -$295.253 million, Q2 2026 free cash flow was -$81.162 million, and operating cash flow was -$80.730 million — and the company relied on $113.611 million of common stock issuance in Q2 2026 to bolster cash, ending the period with $62.619 million in cash after deploying $462.444 million into investments. ROE of -15.84% and ROA of -12.03% confirm that capital is being consumed rather than compounded, so while the low leverage and high current ratio reduce near-term solvency risk, continued equity dilution is a real risk if burn persists at current levels.
Quarterly Revenue
$44687000.0B
2026-06
Revenue YoY Growth
+25.7%
YoY Comparison
Gross Margin
-28.1%
Latest Quarter
Free Cash Flow
$-295253000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GRAL Overvalued?
Because GRAIL's net income is negative (trailing EPS of -$0.13 and Q2 2026 net income of -$110.247 million), the PE ratio is not meaningful — the trailing PE of -7.70 and forward PE of -17.39 are both negative and therefore uninformative for valuation. I therefore lead with the price-to-sales ratio, which at 21.37x trailing sales is the most relevant metric for a pre-profit, high-growth diagnostics company, supplemented by the EV/Sales of 31.17x; the gap between the trailing PS of 21.37x and the forward-looking revenue estimates implies the market expects substantial top-line growth to bring the multiple down over time. The negative EV/EBITDA of -7.92x and negative PCF of -10.52x further confirm that cash-flow-based metrics are unusable here, leaving sales-based valuation as the only viable anchor. On a peer basis, a PS of 21.37x is a steep premium to typical diagnostics and life-sciences tools companies, which often trade in the mid-single-digit to low-double-digit sales multiples; even allowing for GRAIL's MCED optionality, the stock is priced for near-flawless execution. The PEG ratio of 0.093 is distorted by negative earnings and should not be read as a value signal. The premium is arguably justified only if Galleri achieves FDA approval and broad reimbursement, which would transform the revenue base — without that catalyst, the multiple is vulnerable to sharp compression. Historically, GRAIL's own PS ratio has ranged from roughly 14.5x (Q2 2024) to 79.95x (Q4 2025), and the current 21.37x sits in the lower-middle portion of that band, suggesting that relative to its own history the stock is not at peak valuation even after the recent price surge. The PB ratio of 1.22 is modest and reflects a relatively asset-light balance sheet with substantial cash and investments, though the negative ROE of -15.84% means book value is being eroded by losses. The key takeaway is that valuation is entirely a function of future revenue scale and the probability-weighted FDA/reimbursement outcome; at 21.37x sales the market is embedding a high probability of success, so any negative regulatory or payer development would likely trigger severe multiple compression.
PE
-7.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-7.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are severe: GRAIL generated Q2 2026 revenue of $44.687 million but posted a net loss of $110.247 million, with a negative gross margin of -28.12% and operating expenses of $161.217 million. The company burned $81.162 million in free cash flow in Q2 alone, and trailing twelve-month free cash flow is -$295.253 million, necessitating frequent equity raises—$113.611 million in common stock was issued in Q2 2026. While the balance sheet is strong with a current ratio of 11.97 and debt-to-equity of 0.038, persistent dilution erodes shareholder value and the path to profitability remains uncertain without reimbursement scale. Revenue is entirely dependent on Galleri, making this a single-product bet with lumpy sequential growth (Q4 2025 revenue of $43.597 million exceeded Q1 2026's $40.785 million).
Market and competitive risks are amplified by the stock's extreme valuation and volatility. At a PS ratio of 21.37x and EV/Sales of 31.17x, GRAL trades at a significant premium to diagnostics peers, leaving it vulnerable to multiple compression if growth disappoints or FDA approval is delayed. The beta of 3.254 means the stock is over three times as volatile as the S&P 500, so a 10% market drawdown could translate into a 30%+ decline. Competitive threats from other MCED developers and potential regulatory hurdles—such as the failed NHS trial—could undermine Galleri's first-mover advantage. Recent news highlights the binary nature of the FDA catalyst, with headlines framing GRAL as a high-risk, high-reward play, and the short ratio of 12.29 suggests fragile positioning that could unwind rapidly.
In a worst-case scenario, FDA rejection or delayed reimbursement would trigger a collapse in the stock price. The 52-week low is $41.50, and the analyst low target is $60.00, implying downside of -58% to -71% from the current price of $143.26. A breakdown below the September breakout support at $107-108 would signal the squeeze has exhausted, potentially leading to a retracement toward the pre-catalyst base near $45-50. Given the max drawdown of -62.92% within the past year, investors could lose over 60% of their capital if the regulatory catalyst fails and cash burn forces further dilution. The combination of high valuation, negative margins, and binary events makes this a highly speculative investment.
FAQ
The most severe risk is regulatory: FDA rejection or delay for Galleri would likely cause a sharp sell-off, with the analyst low target of $60 implying -58% downside. Financial risks are also high, with a cash burn of $295 million annually and negative gross margins (-28.12%), necessitating dilutive equity raises. Competitive risks include other MCED developers potentially launching superior tests, eroding Galleri's first-mover advantage. Macro risks are amplified by the stock's beta of 3.254, meaning a market downturn could disproportionately impact GRAL. Additionally, the short ratio of 12.29 indicates fragile positioning that could unwind rapidly.
The 12-month forecast is highly uncertain, with a base case (50% probability) targeting $100-130, a bull case (25%) targeting $175-200, and a bear case (25%) targeting $60-80. The base case assumes steady revenue growth and a delayed but eventual FDA approval, while the bull case requires timely approval and broad reimbursement. The bear case reflects regulatory failure or commercial disappointment. The most likely scenario is the base case, with the stock trading around the analyst average target of $112.40, but investors should be prepared for extreme volatility given the binary nature of the catalyst.
GRAL appears overvalued on traditional metrics, with a PS ratio of 21.37x and EV/Sales of 31.17x, well above diagnostics peers that typically trade in the mid-single-digit to low-double-digit sales multiples. The negative PE and PEG ratios are not meaningful due to lack of earnings. Relative to its own history, the current PS is in the lower-middle of its range (14.5x to 79.95x), but that range reflects extreme volatility. The market is pricing in a high probability of FDA approval and successful commercialization, leaving little room for error. If Galleri fails to gain traction, the multiple could compress sharply toward peer levels, implying significant downside.
GRAL is a high-risk, high-reward stock that may be suitable for aggressive investors, but it is not a good buy for most at current levels. The analyst consensus is 'buy' with an average target of $112.40, implying -21.5% downside from the current price of $143.26, suggesting the stock is overextended after a 121% one-year rally. The bull case hinges on FDA approval and reimbursement for Galleri, which could drive the stock to $175, but the bear case targets $60 if regulatory or commercial setbacks occur. With a beta of 3.254 and negative gross margins, the risk/reward is skewed to the downside. Investors should wait for a pullback to the $107-108 support zone or clearer regulatory visibility before considering a position.
GRAL is more suitable for long-term, risk-tolerant investors who can withstand significant volatility, as the investment thesis depends on FDA approval and reimbursement over the next 2-3 years. Short-term trading is extremely risky due to the stock's beta of 3.254 and max drawdown of -62.92%, with sharp moves driven by news flow. The lack of dividends and negative earnings make it unsuitable for income investors. A minimum holding period of 2-3 years is recommended to allow for regulatory and commercial milestones to play out, but position sizing should be small to manage risk.